4-amino-2-methoxyphenyl acetate | 71573-23-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 4-amino-2-methoxyphenyl acetate
• 英文别名: 4-Acetoxy-3-methoxyaniline；(4-amino-2-methoxyphenyl) acetate
• CAS: 71573-23-4
• 化学式: C₉H₁₁NO₃
• 分子量: 181.191
• InChiKey: MPDOIIJUXYHTJH-UHFFFAOYSA-N

物化性质

• 沸点：
  286.9±25.0 °C(Predicted)
• 密度：
  1.181±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-amino-2-methoxyphenyl acetate 在 dowtherm A 、 三氯氧磷 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 9.0h， 生成 4-氯-7-甲氧基-6-喹啉醇
  参考文献：
  名称：

  WO2006/117552

  摘要：

  公开号：
• 作为产物：
  描述：

  2-methoxy-4-nitrophenyl acetate 在 palladium on activated charcoal 、 氢气 作用下， 以 乙醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 以78%的产率得到4-amino-2-methoxyphenyl acetate
  参考文献：
  名称：

  放射性标记的谷氨酰胺基环化酶抑制剂 [ 11 C] PBD150的合成和评估，可在淀粉样β聚集之前潜在地检测阿尔茨海默氏病†

  摘要：

  1-（3-（1 H-咪唑-1-基）丙基）-3-（4-羟基-3-甲氧基苯基）硫脲的苯酚被碳11标记选择性生成[ 11 C] PBD150，收率7.3％来自[ 11 C]三氟甲磺酸甲酯（未衰减校正；放射化学纯度≥95％，比活= 5.7 Ciμmol -1，n = 5）。通过小动物PET成像（小鼠和大鼠）对[ 11 C] PBD150的评估确定它没有渗透到血脑屏障中，表明先前描述的对转基因小鼠的治疗作用可能不是抑制中枢神经系统谷氨酰胺酰环化酶的结果。

  DOI：

  10.1039/c5md00148j

文献信息

• Quinoline derivatives inhibiting the effect of growth factors such as VEGF
  申请人：Zeneca Limited

  公开号：US06809097B1

  公开（公告）日：2004-10-26

  Compounds of the formula (I): wherein: R2 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; n is an integer from 0 to 5; Z represents —O—, —NH—, —S— or —CH2—; G1 represents phenyl or a 5-10 membered heteroaromatic cyclic or bicyclic group; Y1, Y2, Y3 and Y4 each independently represents carbon or nitrogen; R1 represents fluoro or hydrogen; m is an integer from 1 to 3; R3 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, —NR4R5 (wherein R4 and R5, can each be hydrogen or C1-3alkyl), or a group R6—X1— wherein X1 represents —CH2— or a heteroatom linker group and R6 is an alkyl, alkenyl or alkynyl chain optionally substituted by for example hydroxy, amino, nitro, alkyl, cycloalkyl, alkoxyalkyl, or an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring, which alkyl, alkenyl or alkynyl chain may have a heteroatom linker group, or R6 is an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals such as humans, processes for the preparation of such derivatives, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula I. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

  公式(I)的化合物： 其中：R2代表羟基，卤素，C1-3烷基，C1-3烷氧基，C1-3烷酰氧基，三氟甲基，氰基，氨基或硝基；n是0到5之间的整数；Z代表—O—，—NH—，—S—或—CH2—；G1代表苯基或一个5-10员的杂芳环状或双环状基团；Y1、Y2、Y3和Y4各自独立代表碳或氮；R1代表氟或氢；m是1到3之间的整数；R3代表氢，羟基，卤素，氰基，硝基，三氟甲基，C1-3烷基，—NR4R5（其中R4和R5各自可以是氢或C1-3烷基），或一个R6—X1—基团，其中X1代表—CH2—或一个杂原子连接基团，R6是一个烷基、烯基或炔基链，该链可选地被例如羟基、氨基、硝基、烷基、环烷基、烷氧基烷基或一个可选地被取代的吡啶酮、苯基和杂环环取代，该烷基、烯基或炔基链可能含有一个杂原子连接基团，或者R6是一个可选地被取代的吡啶酮、苯基和杂环环，以及它们的盐，用于制造一种药物，用于在温血动物如人类中产生抗血管生成和/或降低血管通透性的效果，制备这类衍生物的过程，包含公式I的化合物或其药物可接受的盐作为活性成分的药物组合物，以及公式I的化合物。公式I的化合物及其药物可接受的盐抑制VEGF的效果，这一特性在治疗包括癌症和类风湿性关节炎在内的多种疾病状态中具有价值。
• Total syntheses of (±)-musellarins A–C
  作者：Zhilong Li、Tsz-Fai Leung、Rongbiao Tong

  DOI：10.1039/c4cc05248j

  日期：——

  The first, diastereoselective total syntheses of musellarins A-C were achieved concisely with 7.8-9.8% yields in 15-16 steps. The key synthetic features include (i) an Achmatowicz rearrangement, Kishi reduction, and Friedel-Crafts cyclization to construct the tricyclic framework and (ii) Heck coupling of aryldiazonium salts to introduce the aryl group into the dihydropyran in a 2,6-trans fashion in

  以15-16个步骤的7.8-9.8％的收率，简明地实现了musellarins AC的第一个非对映选择性总合成。关键的合成特征包括（i）Achmatowicz重排，Kishi还原和Friedel-Crafts环化以构建三环骨架，以及（ii）芳基重氮盐的Heck偶联，以2,6-反式的方式将芳基引入二氢吡喃中在合成的最后阶段。
• NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
  申请人：Washburn William N.

  公开号：US20080269110A1

  公开（公告）日：2008-10-30

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I where R 1 , R 1a , R 1b , A, R 3 , R 4 , R 5 , R5 b and R 6 are as defined herein.

  本申请提供了根据式I提供的化合物，包括所有立体异构体、溶剂合物、前药和药用可接受形式。此外，本申请提供了含有至少一种根据式I的化合物和可选至少一种额外治疗剂的药物组合物。最后，本申请提供了治疗患有MCHR-1调节性疾病或紊乱的患者的方法，例如肥胖症、糖尿病、抑郁症或焦虑症，通过给予根据式I的化合物的治疗有效剂量。其中R1、R1a、R1b、A、R3、R4、R5、R5b和R6如本文所定义。
• OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
  申请人：Wellmarker Bio Co., Ltd.

  公开号：EP4011885A1

  公开（公告）日：2022-06-15

  An oxo-pyridine fusion ring derivative compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof according to the present invention effectively inhibits the activity of RON and can not only effectively suppress the cell growth of cancer cell lines in which RON is activated, but also can effectively kill the cancer cell lines. Therefore, the oxo-pyridine fusion ring derivative compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof according to the present invention can be advantageously used for preventing or treating a disease associated with protein kinase activity.

  根据本发明，化学式1所代表的一种氧代吡啶融合环衍生物化合物或其药学上可接受的盐，可以有效抑制RON的活性，不仅可以有效抑制RON被激活的癌细胞系的细胞生长，还可以有效杀死癌细胞系。因此，根据本发明，化学式1所代表的氧代吡啶融合环衍生物化合物或其药学上可接受的盐可以有利地用于预防或治疗与蛋白激酶活性相关的疾病。
• Non-basic melanin concentrating hormone receptor-1 antagonists
  申请人：Bristol-Myers Squibb Company

  公开号：US07851622B2

  公开（公告）日：2010-12-14

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I where R1, R1a, R1b, A, R3, R4, R5, R5b and R6 are as defined herein.

  本申请提供了按照公式I提供的化合物，包括所有立体异构体、溶剂合物、前药和药学上可接受的形式。此外，本申请还提供了含有至少一种按照公式I的化合物的药物组合物，并可选地含有至少一种额外的治疗剂。最后，本申请提供了通过给予按照公式I的化合物的治疗有效剂量来治疗患有MCHR-1调节性疾病或疾患，例如肥胖症、糖尿病、抑郁症或焦虑症的患者的方法，其中R1、R1a、R1b、A、R3、R4、R5、R5b和R6如本文所定义。